Pharmacogenomics: Will it change the field of medicine?

Clinica Chimica Acta

Volumn 308, Issue 1-2, 2001, Pages 1-8

  Wieczorek, Stacey J ^a   Tsongalis, Gregory J ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Enzymes; Pharmacogenomics; Polymorphism

Indexed keywords

ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CARRIER PROTEIN; CISAPRIDE; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DIGITALIS GLYCOSIDE; DIGOXIN; DRUG RECEPTOR; FEXOFENADINE; FORMOTEROL; ISOPRENALINE; MACROLIDE; MIBEFRADIL; PROTEINASE INHIBITOR; RIFAMPICIN; SALBUTAMOL; SIMVASTATIN; TERFENADINE; TROGLITAZONE; XANTHINE DERIVATIVE;

CYSTIC FIBROSIS; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TRANSPORT; EXERCISE; GASTROINTESTINAL DISEASE; HISTORY OF MEDICINE; HUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW;

BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOCHROME P-450 ENZYME SYSTEM; DRUG CARRIERS; EXERCISE; FORECASTING; HUMANS; MEMBRANE GLYCOPROTEINS; PEPTIDYL-DIPEPTIDASE A; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

DIGITALIS; STAPHYLOCOCCUS PHAGE 3A;

EID: 0034966859     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(01)00419-3     Document Type: Review

References (55)

1. Human drug-metabolizing enzyme polymorphisms: Effects on risk of toxicity and cancer
2. Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist?
3. Genetic epidemiology of environmental toxicity and cancer susceptibility: Human allelic polymorphisms in drug metabolizing genes, their functional importance and nomenclature issues
4. Moderne probleme der humangenetik
5. Populations and genetic polymorphisms
6. Metabolic effects of pyrimidines derived from fava bean glycosides on human erythrocytes deficient in glucose-6-phosphate dehydrogenase
7. In-vitro-effect of a fava bean extract and of its fractions on reduced glutathione in glucose-6-phosphate dehydrogenase deficient red cells
8. Studies in human inheritance: IX. The inheritance of taste deficiency in man
9. Pharmacogenetics of alcohol sensitivity
10. Accumulation of acetaldehyde in alcohol-sensitive Japanese: Relation to ethanol and acetaldehyde oxidizing capacity
11. Tertiary structure of sickle cell hemoglobin and its functional significance
12. The effect of beta 73 Asn on the interactions of sickling hemoglobins
13. Apolipoprotein E alleles and risk of coronary disease: A meta analysis
14. Relationship of apolipoprotein E phenotype to myocardial infarction and mortality from coronary heart disease
15. Polymorphisms of the apolipoprotein E gene and severity of heart disease as defined by angiography
16. The apolipoprotein ε4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: A substudy of the scandinavian simvastatin survival study
17. Drug-related morbidity and mortality
18. Molecular genetics of the P-450 superfamily
19. Molecular basis of cardiovascular drug metabolism implications for predicting clinically important drug interactions
20. Role of pharmacokinetics and metabolism in drug discovery and development
21. Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: Evaluation of model drugs terfenadine and rifampin
22. P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans
23. Clinical pharmacokinetics of mibefradil
24. Rhabdomyolysis due to interaction of simvastatin with mibefradil
25. Case report: Rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine ans simvastatin
26. Where does clinical pharamcology meet with pharmacogentics in clinical trial analysis?
27. Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to the United States food and drug administration
28. Clinical pharmacokinetics of troglitazone
29. Troglitazone increases cytochrome P-4503A protein and activity in primary cultures of human hepatocytes
30. Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: In vitro studies of potential co-medication interactions
31. A mechanism for the proarrhythmic effects of cisapride (propulsid): High affinity blockade of the human cardiac potassium channel HERG
32. Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: Affinity for open and inactivated states
33. Review article: Cardiac adverse effects of gastrointestinal prokinetics
34. Role of P-glycoprotein in drug disposition
35. Multidrug-resistance transporters
36. Functional polymorphisms of the human mutidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
37. Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: A report from the cystic fibrosis genetic analysis consortium
38. Defective intercellular transport and processing of CFTR is the molecular basis of most cystic fibrosis
39. Pharmacology of CFTR chloride channel efflux from cystic fibrosis cells
40. Pharmacogenomics of the cystic fibrosis transmembrane conductance regulator (CFTR) and the cystic fibrosis drug CPX using genome microarray analysis
41. A meta analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction
42. Angiotension-converting enzyme gene polymorphism is associated with cartoid arterial wall thickness in non-insulin dependent diabetic patients
43. Influence of angiotension-converting enzyme and angiotension II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients
44. 2-adrenergic receptor within the fourth membrane alters ligand binding and functional properties of the receptor
45. 2-adrenergic receptor impart distinct agonist-promoted regulatory properties
46. 2-adrenergic receptor function
47. 2-adrenergic receptor and asthma
48. Plasma histamine, epinephrine, cortisol and leukocyte β-adrenergic receptors in nocturnal asthma
49. 2-adrenergic receptor polymorphism with lower airway reactivity in asthmatic subjects
50. 2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure
51. Endocrine responses to exercise
52. Genomics, genes, and environment interaction: The role of exercise
53. Exercise training-induced blood pressure and plasma lipid improvements in hypertensives may be genotype dependent
54. 2-cholesterol levels in overweight men